IRIS PubliCatt

Laurenti, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.670
EU - Europa 7.725
AS - Asia 2.099
OC - Oceania 109
AF - Africa 75
SA - Sud America 47
Continente sconosciuto - Info sul continente non disponibili 10
Totale 18.735
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.553
DE - Germania 2.180
SE - Svezia 1.672
CN - Cina 1.325
IT - Italia 1.214
UA - Ucraina 670
IE - Irlanda 520
FR - Francia 377
GB - Regno Unito 335
SG - Singapore 331
RU - Federazione Russa 219
FI - Finlandia 179
IN - India 151
AU - Australia 93
TR - Turchia 93
CA - Canada 87
PL - Polonia 76
NL - Olanda 44
CI - Costa d'Avorio 42
HK - Hong Kong 35
BE - Belgio 33
JP - Giappone 33
IR - Iran 26
ES - Italia 25
BR - Brasile 24
CZ - Repubblica Ceca 24
MX - Messico 24
HU - Ungheria 22
RO - Romania 20
CH - Svizzera 17
AT - Austria 16
NZ - Nuova Zelanda 16
GR - Grecia 15
KR - Corea 15
PT - Portogallo 12
EG - Egitto 11
ID - Indonesia 11
IL - Israele 11
TH - Thailandia 11
VN - Vietnam 10
CL - Cile 9
DZ - Algeria 8
NO - Norvegia 8
SA - Arabia Saudita 7
AR - Argentina 6
EU - Europa 6
HR - Croazia 6
SK - Slovacchia (Repubblica Slovacca) 6
BG - Bulgaria 5
LB - Libano 5
MY - Malesia 5
NP - Nepal 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AE - Emirati Arabi Uniti 4
BZ - Belize 4
MA - Marocco 4
MK - Macedonia 4
PK - Pakistan 4
ZA - Sudafrica 4
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
EE - Estonia 3
GE - Georgia 3
MD - Moldavia 3
PE - Perù 3
RS - Serbia 3
BD - Bangladesh 2
CM - Camerun 2
CO - Colombia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
JO - Giordania 2
LI - Liechtenstein 2
PH - Filippine 2
TW - Taiwan 2
UY - Uruguay 2
CY - Cipro 1
EC - Ecuador 1
IQ - Iraq 1
IS - Islanda 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MC - Monaco 1
MM - Myanmar 1
MN - Mongolia 1
MT - Malta 1
SC - Seychelles 1
SI - Slovenia 1
UZ - Uzbekistan 1
Totale 18.735
Salva come PNG Salva come JPEG
Città #
Chandler 1.400
Ashburn 634
Dublin 506
Jacksonville 412
San Mateo 354
Dearborn 303
Nanjing 299
Wilmington 266
Beijing 236
Milan 225
Ann Arbor 215
New York 191
Singapore 191
Florence 176
Boston 175
Cattolica 168
Woodbridge 144
Moscow 140
Redwood City 140
Houston 130
Lawrence 130
Princeton 127
Nanchang 121
Nürnberg 121
Rome 115
Seattle 115
Marseille 105
Redmond 104
Lancaster 103
Fairfield 96
Munich 91
Los Angeles 89
Izmir 82
Bremen 79
Kunming 79
Chicago 64
Mountain View 55
Warsaw 54
Boardman 52
Shenyang 52
Norwalk 49
Abidjan 42
Washington 42
Tianjin 41
Zhengzhou 41
Hefei 38
Pune 38
Hebei 37
Cambridge 34
Jiaxing 34
Hangzhou 33
Changsha 31
Auburn Hills 30
Guangzhou 30
Brussels 29
Helsinki 27
Hong Kong 27
London 24
Philadelphia 24
Shanghai 24
Leawood 22
Minneapolis 22
Fremont 21
University Park 21
Busto Arsizio 20
Phoenix 19
Brisbane 18
Detroit 18
Jinan 18
Toronto 18
Lanzhou 17
Adelaide 16
Albany 16
Augusta 16
Changchun 16
Brno 15
San Francisco 15
Bologna 14
Brooklyn 14
Budapest 13
Falls Church 12
Melbourne 12
Portland 12
San Diego 12
Sydney 12
Buffalo 11
Padova 11
Seoul 11
Turin 11
Amsterdam 10
Auckland 10
Chengdu 10
Saint Petersburg 10
Simi Valley 10
Stockholm 10
Vienna 10
Atlanta 9
Bangkok 9
Berlin 9
Garden City 9
Totale 9.373
Salva come PNG Salva come JPEG
Nome #
VITAMIN B12 DEFICIENCY: CORRELATION BETWEEN MTHFR POLYMORPHISMS AND CLINICAL AND LABORATORY FINDINGS 1.819
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 589
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS 348
Reliability of leukostasis grading score to identify patients with high-risk hyperleukocytosis 300
Factors associated with mortality in bacteremic patients with hematologic malignancies. 295
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 281
Factors associated with mortality in bacteremic patients with hematologic malignancies. 159
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 144
Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome 141
Prospective study of hepatitis B virus reactivation in patients with hematological malignancies 140
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation 139
Correlation between paraproteinaemia and viral reactivation after allo-SCT 134
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments 134
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. 132
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma. A pilot study. 129
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 129
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation 124
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia 122
Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: Safety and efficacy evaluation. 114
Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy 112
Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic stem cell transplant recipients 112
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 111
Chronic lymphocytic leukemia with eyelid involvement responding to alemtuzumab. 109
All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients 106
Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication 105
Role of 18F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients. 102
revalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. 102
Guillain-Barre' syndrome following Varicella zoster reactivation in Chronic Lymphocytic Leukemia treated with fludarabine 101
AB0 type does not affect platelet engraftment after autologous peripheral blood stem cell transplant in a series of 249 hematologic patients 100
EXTREME THROMBOCYTOSIS IN CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS 100
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration 99
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia 99
The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia. Leukemia. 98
Role of (18)F-FDG PET-CT for evaluating the response to reduced-intensity conditioning allogeneic transplant in heavily pre-treated patients with chronic lymphocytic leukemia: preliminary results in nine patients 98
Work related acute leukemia and mucor mycosis in a boat-builder 97
New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia 97
Hyperleukocytosis and leukostasis: management of a medical emergency 97
Hyperleukocytosis and leukostasis: management of a medical emergency 96
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation 95
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 95
H1N1 Influenza among Hematological Patients: Monocentric Influenza Cases from 2011 to 2016 94
Neurologic improvement after peripheral blood stem cell transplantation in poems 93
Usefulness of F-18 FDG PET/CT in the follow-up of POEMS syndrome after autologous peripheral blood stem cell transplantation 91
Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy 91
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue 91
Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström's macroglobulinaemia. 90
Mycosis fungoides as a cause of severe obstructive sleep apnea 90
Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience 90
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 89
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 88
Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units 87
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 86
Non-tunnelled central venous catheters in adult stem cell transplantation recipients: an effective option 86
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 86
Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation 84
Invasive fungal infections in chronic lymphoproliferative disorders: A monocentric retrospective study 84
Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study 83
TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients 82
Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience 81
Granulocyte transfusions as adjunctive treatment of invasive fungal diseases in neutropenic patients 81
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia 81
Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome 80
The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia 79
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 78
High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia 77
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 77
B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia 76
Reduced-intensity conditioning allogeneic transplant in heavily pre-treated chronic lymphocytic leukaemia patients: a single centre experience 76
Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study 75
Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group 72
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 71
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL 70
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 69
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia 68
Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia 68
Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers 68
The Syk kinase as a therapeutic target in leukemia and lymphoma 67
Chronic Lymphocitic Leukaemia: Census of Patients Treated in Italian Haematology Units 67
Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections. 67
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid 67
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 66
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 65
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 65
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 65
High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders 64
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. 64
Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia. 63
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma. 63
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 62
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 62
Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia 61
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 61
Unrelated cord blood transplantation and post-transplant cyclophosphamide 61
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen 61
Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease 60
Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients 60
Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients 60
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 59
Massive Pulmonary Embolism at the Onset of Acute Promyelocytic Leukemia 59
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience 59
Totale 11.944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.065
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.065
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.650 466 223 208 184 204 307 242 118 133 180 213 172
2020/20211.552 60 167 50 143 220 115 144 38 193 65 316 41
2021/20222.255 183 130 131 152 168 65 38 322 107 126 426 407
2022/20234.423 631 627 350 544 331 553 197 308 500 87 215 80
2023/20244.053 126 732 201 777 226 502 196 110 133 233 389 428
2024/2025234 234 0 0 0 0 0 0 0 0 0 0 0
Totale 19.123